For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Thinking clearly about two geriatric giants – dementia and delirium
Thinking clearly about two geriatric giants – dementia and delirium

Specialist GP Ngaire Kerse discusses recent research in the dementia/delirium field, which highlights the importance of awareness and prevention
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Ma’u E, Cullum S, Cheung G, et al. Differences in the potential for dementia prevention between major ethnic groups within one country: A cross sectional analysis of population attributable fraction of potentially modifiable risk factors in New Zealand. Lancet Reg Health West Pac 2021;13:100191.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396(10248):413–46.
3. Menzies O, Dudley M, Garrett N, et al. He Tūhononga Whaiaro: A kaupapa Māori approach to mate wareware (dementia) and cognitive assessment of older Māori. J Appl Gerontol 2022;41(4):1066–73.
4. Gibb K, Seeley A, Quinn T, et al. The consistent burden in published estimates of delirium occurrence in medical inpatients over four decades: a systematic review and meta-analysis study. Age Ageing 2020;49(3):352–60.
5. Tsui A, Searle SD, Bowden H, et al. The effect of baseline cognition and delirium on long-term cognitive impairment and mortality: a prospective population-based study. Lancet Healthy Longev 2022;3(4):e232–41.